Organ Perfusion and Cellular Services

What Organ Perfusion and Cellular Services does

Organ Perfusion and Cellular Services (OPCS) is a privately held, veteran-owned healthcare services and biotechnology products company headquartered in Carmel, Indiana. The company operates two interconnected business lines. The first is outsourced organ perfusion services delivered to hospital transplant centers, providing 24/7-365 abdominal and thoracic organ preservation, machine perfusion for kidney and liver, intraoperative and preservation management, supply logistics, and on-site embedded staffing. OPCS is device-agnostic, with personnel cross-trained across six leading perfusion platforms including ORS LifePort, Waters Medical Systems RM4, XVIVO KAT, OrganOx, Bridge to Life Vitasmart, and Paragonix systems (LIVERguard, SherpaPak, BAROguard, PancreasPak).

The second business line is the production and sale of primary hepatocytes — both human and rodent, including plateable variants — isolated from donor organs using proprietary pre-isolation protocols. These products are sold directly to pharmaceutical companies and research institutions for drug discovery, metabolism, and hepatotoxicity studies, and are also offered under wholesale/private-label arrangements that allow partners to brand the products themselves.

OPCS was co-founded by Jeff Hare (CEO) and Nathan Luttrell (COO), with Rob Kaiser (CSO, formerly of CellzDirect, Triangle Research Labs, and Lonza) and Dr. Paul Lange (Medical Director, formerly CMO at three OPOs) rounding out the leadership team. The company and its affiliated entity Transplant Staffing Resources work with 33 Organ Procurement Organizations, including Indiana Donor Network and Gift of Life Michigan, which secures upstream donor organ supply for both service lines. The customer base consists of US transplant centers (perfusion services) and research institutions and pharmaceutical companies (hepatocyte products). With 13 employees at headquarters and a quote-based pricing model, OPCS operates as a focused niche player in the organ transplantation and primary cell supply value chain.

Name

Organ Perfusion and Cellular Services

Legal name

Organ Perfusion and Cellular Services

Website

https://organservices.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Organ Perfusion and Cellular Services (OPCS) is a Carmel, Indiana-based, veteran-owned company that provides outsourced 24/7 organ perfusion services to US transplant centers and sells primary human and rodent hepatocytes to pharmaceutical and research customers, leveraging relationships with 33 OPOs.

Ownership category

akta.pro rank

Product category

Organ Perfusion and Transplant Support Services

NAICS

Medical and Diagnostic Laboratories (6215), Outpatient Care Centers (6214)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071)

akta.pro primary industry

Transplant Hepatology (HLAKAEAK)

akta.pro secondary industry

Blood, Organ & Tissue Donation Organizations (BPAGACAJ)

Keywords

• Organ perfusion services
• Primary hepatocyte isolation
• Transplant center support
• Machine perfusion outsourcing
• Hepatocyte cell products

Headquarters

HQ city

Carmel

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Organ Perfusion Services: Provides comprehensive organ perfusion services to transplant centers including on-site perfusion center setup, 24/7 staffing, supply management, and organ preservation management. Services cover abdominal and thoracic organs (kidney, liver, heart, lung, pancreas).
2. Primary Hepatocyte Products: Sale of primary human and rodent hepatocytes for research purposes. Products include standard lots and custom isolations with certificates of analysis. Wholesale pricing available for resellers maintaining their own branding.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Organ Perfusion and Cellular Services delivers turn-key outsourced organ perfusion services to U.S. transplant centers, including 24/7 flyout support, on-site staffing, supply management, and machine perfusion for kidney, liver, heart, lung, and pancreas organs. The company also isolates and sells primary human and rodent hepatocytes (standard and plateable variants) to research institutions and pharmaceutical companies for use in drug discovery, metabolism studies, and toxicology testing.

Product overview

Organ Perfusion and Cellular Services offers two interconnected service lines: (1) Primary Hepatocyte Products including Human Hepatocytes and Rodent Hepatocytes (both standard and plateable variants), which are isolated from donor organs using optimized protocols for research applications; and (2) Organ Perfusion Services providing turn-key outsourcing for transplant centers including 24/7 flyout coordination, on-site perfusion staff, and machine perfusion for abdominal and thoracic organs using various perfusion devices. The hepatocyte products support pharmaceutical research, drug discovery, and toxicology studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Organ Perfusion Services Turn-key outsourced organ perfusion services for transplant centers including 24/7/365 flyout support, organ preservation, liver and kidney machine perfusion, intraoperative and preservation management, supply management, and on-site staffing. Supports kidney, liver, heart, lung, and pancreas transplants using devices including ORS LifePort Kidney Transporter, Waters Medical Systems RM4, XVIVO, OrganOx, Bridge to Life, and Paragonix systems.
• Human Hepatocytes Primary human hepatocytes isolated from donor organs for research applications. Available as standard and plateable variants with Certificates of Analysis, and through wholesale/private-label arrangements for resellers.
• Rodent Hepatocytes Primary hepatocytes isolated from rodent species (mice, rats) for research applications. Available in multiple lot sizes with standard and plateable variants, with Certificates of Analysis.

Quantifiable outcome

• Lower frequency of failed hepatocyte isolations compared to industry standard
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• 33 Organ Procurement Organizations (OPOs)coreStrategic or Co-development PartnerOPCS team works with 33 OPOs including Indiana Donor Network and Gift of Life Michigan to provide services in all aspects of organ and tissue recovery. Strong OPO relationships ensure consistent supply of healthy cells and organs for both transplant and research purposes.
• Transplant Staffing ResourcescoreStrategic or Co-development PartnerRelated entity founded by CEO Jefferson Hare specializing in providing staffing solutions for Organ Procurement Organizations. Provides over 160 contract employees including organ coordinators, family services coordinators, organ preservationists, tissue recovery technicians and remote call center staff. OPCS was inspired by the need to bridge gaps between OPOs and transplant centers.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• TransMedics: Public medical device company whose Organ Care System (OCS) is used for heart, lung, and liver perfusion. TransMedics overlaps with OPCS in serving US transplant centers and could expand into on-site perfusion services, making it both a customer-adjacent partner and a potential competitive threat.
• Organ Recovery Systems (LifePort): Manufacturer of the LifePort Kidney Transporter, a foundational kidney perfusion device used widely across US transplant centers. OPCS specifically names LifePort among the systems its team operates, making Organ Recovery Systems a close ecosystem peer.
• OrganOx: Manufacturer of the metra normothermic liver perfusion device. OPCS's team is specifically cross-trained on OrganOx systems, making it both an enablement partner and a potential vertical integrator of outsourced liver perfusion services.
• XVIVO Perfusion: Provider of the XPS and KAT (Kidney Assist Transport) perfusion systems, including the STEEN solution for lungs. OPCS staff are cross-trained on XVIVO systems, and XVIVO is a natural adjacent competitor for outsourced perfusion in lung and kidney.
• Paragonix Technologies: Developer of organ transport devices including LIVERguard, SherpaPak, BAROguard, and PancreasPak — all of which OPCS uses on behalf of customers. Paragonix has signaled interest in service-layer offerings that could compete with OPCS's perfusion staffing model.

Emerging players

• Bridge to Life: Developer of the VitaSmart and other organ preservation devices. OPCS cross-trains on Bridge to Life equipment, making the company a partial peer in perfusion technology and a potential service-layer competitor going forward.
• BioIVT: Supplier of human primary cells and tissues for research, including hepatocytes, with comparable offerings to OPCS in the drug-discovery and academic research market. BioIVT is a relevant competitor for OPCS's wholesale and direct hepatocyte sales.
• Waters Medical Systems: Manufacturer of the RM4 kidney perfusion system, which OPCS's team operates on behalf of transplant centers. Waters Medical is an adjacent peer in the kidney-machine-perfusion space and a candidate to evolve into services competition.

Direct peers

• SpecialtyCare: Largest US provider of outsourced perfusion services, primarily for cardiac surgery. SpecialtyCare shares OPCS's core business model — embedded clinical staff, 24/7 coverage, hospital contracts — and represents the most directly comparable outsourced perfusion staffing peer, albeit in cardiac rather than transplant.
• Lonza: Global life-sciences tools giant that acquired CellzDirect and Triangle Research Labs (former employers of OPCS's CSO). Lonza is the dominant commercial supplier of primary human and rodent hepatocytes and competes head-on with OPCS's hepatocyte product line on yield, quality, and price.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/organ-perfusion-and-cellular-services

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Organ Perfusion and Cellular Services